{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:58:15Z","timestamp":1790956695009,"version":"4.1.0"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n One in 100 adolescents and young adults (hereafter \u201cyouths\u201d) in the US has an opioid use disorder (OUD), yet little is known about the extent to which they receive care aligned with national quality measures.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate progression through the OUD cascade of care (COC) among Medicaid-enrolled youths, with key stages of treatment aligned with national quality measures.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used enrollment and health insurance claims from all US states and Washington, DC, from the 2016-2023 Transformed Medicaid Statistical Information System Analytic Files. Participants had OUD and were aged 13 to 25 years. Data were analyzed from November 3, 2025, to July 24, 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Diagnosis of OUD and receipt of addiction treatment, including behavioral health services and medications for OUD (MOUD; buprenorphine, methadone, or extended-release naltrexone).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Progression through COC stages aligned with national quality measures: treatment initiation, engagement, MOUD receipt, and 180-day MOUD retention.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 229\u202f847 youths with OUD enrolled in Medicaid (median age, 22 [IQR, 20-24] years; 117\u202f920 females [51.3%]), 116\u202f458 (50.7%) initiated treatment within 14 days of diagnosis, and 75 614 (32.9%) engaged in care (ie, had 2 or more additional treatment encounters within 34 days of treatment initiation). Among the 75 614 youths who engaged in treatment, 35 011 (46.3%) received MOUD, representing 15.2% of all 229\u202f847 youths with OUD. However, only 554 of 8352 adolescents younger than 18 years who engaged in treatment received MOUD (6.6%), compared with 34\u202f457 of 67\u202f262 young adults 18 years and older (51.2%). Buprenorphine was the most initiated medication (n\u2009=\u200923 990 of 35 011 [68.5%]), followed by methadone (n\u2009=\u20098911 [25.5%]) and extended-release naltrexone (n\u2009=\u20092110 [6.0%]). Overall, only 7070 of 229\u202f847 youths (3.1%) continued medication for 180 days or more. Among youths receiving MOUD, retention was highest for methadone (n\u2009=\u20092334 of 8911 [26.2%]), followed by buprenorphine (n\u2009=\u20094613 of 23\u202f990 [19.2%]) and extended-release naltrexone (n\u2009=\u2009123 of 2110 [5.8%]). Median time receiving MOUD varied by medication: methadone, 59 days (IQR, 15-189 days); buprenorphine, 45 days (IQR, 18-128 days); and extended-release naltrexone, 31 days (IQR, 28-82 days) (log-rank test,\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Younger adolescents aged 13 to 15 years and racially minoritized youths had consistently lower progression through the COC.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of Medicaid-enrolled youths with OUD, most did not receive timely, evidence-based treatment, and only 1 in 32 received sustained pharmacotherapy. Gaps and persistent disparities exist across the COC, particularly for youths of color, underscoring the need for policies and care models that expand equitable treatment access.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.37263","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:23Z","timestamp":1790955023000},"page":"e2637263","source":"Crossref","is-referenced-by-count":0,"title":["Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths"],"prefix":"10.1001","volume":"9","author":[{"given":"Scott E.","family":"Hadland","sequence":"first","affiliation":[{"name":"Division of Adolescent and Young Adult Medicine, Mass General Brigham for Children, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijeoma","family":"Opara","sequence":"additional","affiliation":[{"name":"Department of Social and Behavioral Sciences, Yale University School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Fung","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Health Policy Research Center, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandi","family":"Dong","sequence":"additional","affiliation":[{"name":"Division of Adolescent and Young Adult Medicine, Mass General Brigham for Children, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitara","family":"Weerakoon","sequence":"additional","affiliation":[{"name":"Department of Social and Behavioral Sciences, Yale University School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rodean","sequence":"additional","affiliation":[{"name":"Independent researcher, Overland Park, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ab\u00e8le C.","family":"Bind","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Biostatistics Center, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie T.","family":"Zima","sequence":"additional","affiliation":[{"name":"Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Glass","sequence":"additional","affiliation":[{"name":"Division of Adolescent and Young Adult Medicine, Mass General Brigham for Children, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Alegr\u00eda","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Karandinos","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Robin","family":"Williams","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, Columbia University, New York, New York"},{"name":"New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"zoi261004r2","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1542\/peds.2019-2056C","article-title":"Management of opioid misuse and opioid use disorders among youth.","volume":"145","author":"Robinson","year":"2020","journal-title":"Pediatrics"},{"issue":"3","key":"zoi261004r3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jadohealth.2020.12.129","article-title":"Medication for adolescents and young adults with opioid use disorder.","volume":"68","author":"Society for Adolescent Health and Medicine","year":"2021","journal-title":"J Adolesc Health"},{"issue":"2","key":"zoi261004r4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMp2312084","article-title":"The overdose crisis among U.S. adolescents.","volume":"390","author":"Friedman","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi261004r5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-069488","article-title":"Changes in synthetic opioid-involved youth overdose deaths in the United States: 2018-2022.","volume":"155","author":"Miller","year":"2025","journal-title":"Pediatrics"},{"key":"zoi261004r6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-070433","article-title":"Polysubstance-involved opioid overdose deaths among US youths: 2020 to 2023.","volume":"156","author":"Buchholz","year":"2025","journal-title":"Pediatrics"},{"issue":"50","key":"zoi261004r7","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.15585\/mmwr.mm7150a2","article-title":"Drug overdose deaths among persons aged 10-19 years: United States, July 2019-December 2021.","volume":"71","author":"Tanz","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"zoi261004r8","first-page":"1","article-title":"Deaths: leading causes for 2023.","volume":"74","author":"Tejada-Vera","year":"2025","journal-title":"Natl Vital Stat Rep"},{"issue":"20","key":"zoi261004r9","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1056\/NEJMc2201761","article-title":"Current causes of death in children and adolescents in the United States.","volume":"386","author":"Goldstick","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi261004r10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders.","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"key":"zoi261004r13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","article-title":"Developing an opioid use disorder treatment cascade: a review of quality measures.","volume":"91","author":"Williams","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi261004r14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1176\/appi.ajp.20220456","article-title":"Performance measurement for opioid use disorder medication treatment and care retention.","volume":"180","author":"Williams","year":"2023","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi261004r19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/08897077.2022.2074604","article-title":"Opioid use disorder Cascade of care framework design: A roadmap.","volume":"43","author":"Williams","year":"2022","journal-title":"Subst Abus"},{"issue":"3","key":"zoi261004r20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamapediatrics.2021.4606","article-title":"Access to medications for opioid use disorder and associated factors among adolescents and young adults: a systematic review.","volume":"176","author":"Pilarinos","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"4","key":"zoi261004r21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-0174","article-title":"The challenges of addressing pediatric quality measurement gaps.","volume":"139","author":"Mangione-Smith","year":"2017","journal-title":"Pediatrics"},{"issue":"10","key":"zoi261004r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.3622","article-title":"The T-MSIS Analytic Files (TAF) Analysis Reporting Checklist: a guide for research using Medicaid claims data.","volume":"6","author":"Schpero","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"11","key":"zoi261004r27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder.","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"2","key":"zoi261004r28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018.","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"zoi261004r29","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-071147","article-title":"Buprenorphine treatment duration and adherence among youth and subsequent health outcomes.","volume":"156","author":"Hadland","year":"2025","journal-title":"Pediatrics"},{"issue":"8","key":"zoi261004r31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014.","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"2","key":"zoi261004r32","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-058755","article-title":"Buprenorphine dispensing among youth aged =19 years in the United States: 2015-2020.","volume":"151","author":"Terranella","year":"2023","journal-title":"Pediatrics"},{"issue":"9","key":"zoi261004r33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamapediatrics.2024.2502","article-title":"Pattern of buprenorphine treatment retention among youth aged 10 to 18 years-US, 2015 to 2021.","volume":"178","author":"Connolly","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"5","key":"zoi261004r34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2024.24121","article-title":"Trends in buprenorphine dispensing among adolescents and young adults in the US.","volume":"333","author":"Lee","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"zoi261004r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.1574","article-title":"State- and county-level geographic variation in opioid use disorder, medication treatment, and opioid-related overdose among Medicaid enrollees.","volume":"4","author":"Lindner","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"11","key":"zoi261004r36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2401177","article-title":"Community-based cluster-randomized trial to reduce opioid overdose deaths.","volume":"391","author":"Samet","year":"2024","journal-title":"N Engl J Med"},{"issue":"4S","key":"zoi261004r37","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jadohealth.2021.10.032","article-title":"Utilizing SBIRT as a framework for transforming how we think about prevention and early intervention for youth and young adults.","volume":"71","author":"Eggleston","year":"2022","journal-title":"J Adolesc Health"},{"issue":"1","key":"zoi261004r38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1210","article-title":"Substance use screening, brief intervention, and referral to treatment.","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"issue":"6","key":"zoi261004r39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/ADM.0000000000001001","article-title":"An exploration of young adults with opioid use disorder and how their perceptions of family members\u2019 beliefs affects medication treatment.","volume":"16","author":"Bagley","year":"2022","journal-title":"J Addict Med"},{"issue":"2","key":"zoi261004r40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2310171","article-title":"Treating opioid use disorder in general practice: diagnosis, harm reduction, and medications.","volume":"390","author":"Bagley","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi261004r41","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1097\/ADM.0000000000001195","article-title":"A qualitative study of barriers and facilitators to integrating medications for opioid use disorder and HIV preexposure prophylaxis for adolescents and young adults.","volume":"17","author":"Herrera","year":"2023","journal-title":"J Addict Med"},{"issue":"22","key":"zoi261004r42","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1001\/jama.2023.6266","article-title":"Treatments used among adolescent residential addiction treatment facilities in the US, 2022.","volume":"329","author":"King","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"zoi261004r43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1377\/hlthaff.2023.00777","article-title":"Adolescent residential addiction treatment in the US: uneven access, waitlists, and high costs.","volume":"43","author":"King","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi261004r44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.20230808","article-title":"Defining discontinuation for buprenorphine treatment: implications for quality measurement.","volume":"181","author":"Williams","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi261004r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States.","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi261004r46","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jadohealth.2020.03.005","article-title":"Adolescent-serving addiction treatment facilities in the United States and the availability of medications for opioid use disorder.","volume":"67","author":"Alinsky","year":"2020","journal-title":"J Adolesc Health"},{"issue":"3","key":"zoi261004r47","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1016\/j.amepre.2020.03.022","article-title":"Opioid use disorder treatment facilities with programs for special populations.","volume":"59","author":"Hadland","year":"2020","journal-title":"Am J Prev Med"},{"key":"zoi261004r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209361","article-title":"Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.","volume":"163","author":"Jaffe","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"zoi261004r49","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-057992","article-title":"Improving substance use prevention, assessment, and treatment financing to enhance equity and improve outcomes among children, adolescents, and young adults.","volume":"150","author":"Camenga","year":"2022","journal-title":"Pediatrics"},{"issue":"2","key":"zoi261004r51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/00952990.2023.2180382","article-title":"Telehealth for opioid use disorder: retention as a function of demographics and rurality.","volume":"49","author":"Williams","year":"2023","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"zoi261004r52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/ADM.0000000000000827","article-title":"Medication for addiction treatment and postpartum health care utilization among pregnant persons with opioid use disorder.","volume":"16","author":"Ahrens","year":"2022","journal-title":"J Addict Med"},{"issue":"3","key":"zoi261004r53","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/08897077.2019.1573209","article-title":"The impact of Medicaid expansion on postpartum health care utilization among pregnant women with opioid use disorder.","volume":"40","author":"Patton","year":"2019","journal-title":"Subst Abus"},{"issue":"5","key":"zoi261004r54","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s11606-020-06339-3","article-title":"Validity of incident opioid use disorder (OUD) diagnoses in administrative data: a chart verification study.","volume":"36","author":"Howell","year":"2021","journal-title":"J Gen Intern Med"},{"key":"zoi261004r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108583","article-title":"Identifying individuals with opioid use disorder: validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse.","volume":"221","author":"Lagisetty","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi261004r1","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2024 National Survey on Drug Use and Health (HHS Publication No. PEP25-07-007, NSDUH Series H-60). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2025. Accessed October 7, 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt56287\/2024-nsduh-annual-national-report.pdf"},{"key":"zoi261004r11","unstructured":"Opioid use disorder treatment for youth: 2020. American Academy of Child and Adolescent Psychiatry. Accessed November 12, 2024. https:\/\/www.aacap.org\/aacap\/Policy_Statements\/2020\/Opioid_Use_Disorder_Treatment_Youth.aspx"},{"key":"zoi261004r12","unstructured":"American Society of Addiction Medicine. Proposed updates to the ASAM Criteria, Fourth Edition, Adolescent Volume. October 1, 2024. Accessed November 1, 2024. https:\/\/downloads.asam.org\/sitefinity-production-blobs\/docs\/default-source\/quality-science\/adolescent-standards-public-comment-fall-2024-final.pdf"},{"key":"zoi261004r15","unstructured":"Centers for Medicare & Medicaid Services. Overview of substance use disorder measures in the 2024 child, adult, and health home core sets. 2024. Accessed January 24, 2025. https:\/\/www.medicaid.gov\/medicaid\/quality-of-care\/downloads\/factsheet-sud-adult-core-set.pdf"},{"key":"zoi261004r16","unstructured":"Substance Abuse and Mental Health Services Administration. Use of pharmacotherapy for opioid use disorder (OUD) (cbe#3400): technical specifications and resource manual. 2024. Accessed October 5, 2024. https:\/\/www.samhsa.gov\/sites\/default\/files\/cbe-3400-technical-specifications-manual.pdf"},{"key":"zoi261004r17","unstructured":"Centers for Medicare & Medicaid Services \/ RAND Corporation. Quality ID #468: Continuity of pharmacotherapy for opioid use disorder (OUD). Accessed January 24, 2025. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2022_Measure_468_MIPSCQM.pdf"},{"key":"zoi261004r18","unstructured":"Counts? N. Medicaid\u2019s role in mental health and substance use care. May 7, 2025. Accessed March 4, 2026. https:\/\/www.commonwealthfund.org\/publications\/explainer\/2025\/may\/medicaids-role-mental-health-and-substance-use-care"},{"key":"zoi261004r22","unstructured":"Centers for Medicare & Medicaid Services. Transformed Medicaid Statistical Information System (T-MSIS) Analytic Files (TAF). September 3, 2024. Accessed June 2, 2025. https:\/\/www.medicaid.gov\/medicaid\/data-systems\/macbis\/medicaid-chip-research-files\/transformed-medicaid-statistical-information-system-t-msis-analytic-files-taf\/index.html"},{"key":"zoi261004r24","unstructured":"STROBE. Strengthening the reporting of observational studies in epidemiology. STROBE. 2026. Accessed March 13, 2026. https:\/\/www.strobe-statement.org\/"},{"key":"zoi261004r25","unstructured":"Centers for Medicare & Medicaid Services. Guidance to state Medicaid agencies on dually eligible beneficiaries receiving medicare opioid treatment services effective January 1, 2020. December 17, 2019. Accessed January 22, 2026. https:\/\/www.medicaid.gov\/federal-policy-guidance\/downloads\/cib121719.pdf"},{"key":"zoi261004r26","unstructured":"Hadland? SE. Opioid use disorder and evidence-based care among Medicaid-enrolled youth: a national cascade of care analysis.? Harvard Dataverse. 2026. Accessed September 10, 2026. https:\/\/dataverse.harvard.edu\/dataset.xhtml?persistentId=doi:10.7910\/DVN\/YYIUND"},{"key":"zoi261004r30","unstructured":"Medicaid and CHIP Business Information Solution. DQ Atlas: race and ethnicity. Centers for Medicare and Medicaid Services. 2025. Accessed November 1, 2025. https:\/\/www.medicaid.gov\/dq-atlas\/landing\/topics\/single\/map?topic=g3m16"},{"key":"zoi261004r50","unstructured":"American Society of Addiction Medicine. Engagement and retention of nonabstinent patients in substance use treatment clinical consideration for addiction treatment providers. 2024. Accessed February 5, 2026. https:\/\/www.asam.org\/quality-care\/clinical-recommendations\/asam-clinicalconsiderations-for-engagement-and-retention-of-non-abstinent-patients-in-treatment"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854760\/hadland_2026_oi_261004_1790346344.15722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:26Z","timestamp":1790955026000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.37263","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}